Body Mass Index and Long-Term Follow-Up Outcomes in Patients With Acute Myocardial Infarction by the Median of Non-HDL Cholesterol: Results From an Observational Cohort Study in China

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2021 Dec 6

PMID 34869654

Authors

Hui Gao

Aidong Shen

Hui Chen

Hongwei Li

Affiliations

Soon will be listed here.

Abstract

The association between obesity, non-HDL cholesterol, and clinical outcomes in subjects with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) is incompletely understood. The aim of this investigation was to explore the association between body mass index (BMI), non-high density lipoprotein (non-HDL) cholesterol, and long-term follow-up prognosis. This present study used data obtained by the Cardiovascular Center of Beijing Friendship Hospital Database Bank. We identified 3,780 consecutive AMI populations aged 25-93 years from 2013 to 2020. Participants were categorized as normal weight (18.5 ≤ BMI <22.9 kg/m), overweight (23.0 ≤ BMI <24.9 kg/m), obese class I (25.0 ≤ BMI <29.9 kg/m), and obese class II (BMI ≥ 30.0 kg/m). The endpoint of interest was cardiovascular (CV) death, all-cause death, myocardial infarction (MI), stroke, unplanned revascularization, and cardiac hospitalization. Participants with higher BMI were younger and more likely to be males compared with lower BMI groups. Elevated non-HDL cholesterol was present in 8.7, 11.0, 24.3, and 5.9% of the normal, overweight, obese class I, and obese class II groups, respectively. After multivariate adjustment, compared to normal-weight participants with decreased non-HDL cholesterol (reference group), obese participants with and without elevated non-HDL cholesterol had a lower risk of mortality (with obese class I and elevated non-HDL cholesterol: hazard ratio [HR] 0.44, 95% confidence interval [CI] 0.28-0.67; with obese class I and decreased non-HDL cholesterol: HR, 0.68, 95% CI, 0.47-0.98; with obese class II and elevated non-HDL cholesterol: HR, 0.42, 95% CI, 0.20-0.87; with obese class II and decreased non-HDL cholesterol: HR, 0.35, 95% CI, 0.16-0.72). In AMI participants performing with PCI, obesity had a better long-term prognosis which probably unaffected by the level of non-HDL cholesterol.

References

. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004; 363(9403):157-63. DOI: 10.1016/S0140-6736(03)15268-3. View

Ma W, Sun X, Wang Y, Han X, Zhu Y, Liu N . Does body mass index truly affect mortality and cardiovascular outcomes in patients after coronary revascularization with percutaneous coronary intervention or coronary artery bypass graft? A systematic review and network meta-analysis. Obes Rev. 2018; 19(9):1236-1247. DOI: 10.1111/obr.12713. View

Barbat-Artigas S, Rolland Y, Vellas B, Aubertin-Leheudre M . Muscle quantity is not synonymous with muscle quality. J Am Med Dir Assoc. 2013; 14(11):852.e1-7. DOI: 10.1016/j.jamda.2013.06.003. View

Ogorodnikova A, Kim M, McGinn A, Muntner P, Khan U, Wildman R . Incident cardiovascular disease events in metabolically benign obese individuals. Obesity (Silver Spring). 2011; 20(3):651-9. PMC: 3494999. DOI: 10.1038/oby.2011.243. View

Morkedal B, Vatten L, Romundstad P, Laugsand L, Janszky I . Risk of myocardial infarction and heart failure among metabolically healthy but obese individuals: HUNT (Nord-Trøndelag Health Study), Norway. J Am Coll Cardiol. 2013; 63(11):1071-8. DOI: 10.1016/j.jacc.2013.11.035. View

Choi S, Kim K, Kim S, Lee G, Jeong S, Park S . Association of Obesity or Weight Change With Coronary Heart Disease Among Young Adults in South Korea. JAMA Intern Med. 2018; 178(8):1060-1068. PMC: 6143106. DOI: 10.1001/jamainternmed.2018.2310. View

Jong C, Li H, Pan S, Hsieh M, Su F, Chen K . Relationship Between Body Mass Index, Antidiabetic Agents, and Midterm Mortality in Patients With Both Type 2 Diabetes Mellitus and Acute Coronary Syndrome. J Am Heart Assoc. 2019; 8(7):e011215. PMC: 6509713. DOI: 10.1161/JAHA.118.011215. View

Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen A, Frikke-Schmidt R, Nordestgaard B . Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2012; 61(4):427-436. DOI: 10.1016/j.jacc.2012.08.1026. View

OBrien E, Fosbol E, Peng S, Alexander K, Roe M, Peterson E . Association of body mass index and long-term outcomes in older patients with non-ST-segment-elevation myocardial infarction: results from the CRUSADE Registry. Circ Cardiovasc Qual Outcomes. 2013; 7(1):102-9. DOI: 10.1161/CIRCOUTCOMES.113.000421. View

10.

Ference B, Ginsberg H, Graham I, Ray K, Packard C, Bruckert E . Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017; 38(32):2459-2472. PMC: 5837225. DOI: 10.1093/eurheartj/ehx144. View

11.

Lovren F, Teoh H, Verma S . Obesity and atherosclerosis: mechanistic insights. Can J Cardiol. 2015; 31(2):177-83. DOI: 10.1016/j.cjca.2014.11.031. View

12.

Boekholdt S, Arsenault B, Mora S, Pedersen T, LaRosa J, Nestel P . Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012; 307(12):1302-9. DOI: 10.1001/jama.2012.366. View

13.

Song Y, Manson J, Meigs J, Ridker P, Buring J, Liu S . Comparison of usefulness of body mass index versus metabolic risk factors in predicting 10-year risk of cardiovascular events in women. Am J Cardiol. 2007; 100(11):1654-8. PMC: 2098701. DOI: 10.1016/j.amjcard.2007.06.073. View

14.

Phillips C . Metabolically healthy obesity across the life course: epidemiology, determinants, and implications. Ann N Y Acad Sci. 2016; 1391(1):85-100. DOI: 10.1111/nyas.13230. View

15.

Alexandre T, Aubertin-Leheudre M, Carvalho L, de Oliveira Maximo R, Corona L, Brito T . Dynapenic obesity as an associated factor to lipid and glucose metabolism disorders and metabolic syndrome in older adults - Findings from SABE Study. Clin Nutr. 2017; 37(4):1360-1366. DOI: 10.1016/j.clnu.2017.06.009. View

16.

Janszky I, Romundstad P, Laugsand L, Vatten L, Mukamal K, Morkedal B . Weight and weight change and risk of acute myocardial infarction and heart failure - the HUNT Study. J Intern Med. 2016; 280(3):312-22. DOI: 10.1111/joim.12494. View

17.

Coutinho T, Goel K, Correa de Sa D, Carter R, Hodge D, Kragelund C . Combining body mass index with measures of central obesity in the assessment of mortality in subjects with coronary disease: role of "normal weight central obesity". J Am Coll Cardiol. 2013; 61(5):553-60. DOI: 10.1016/j.jacc.2012.10.035. View

18.

Sayer A, Dennison E, Syddall H, Gilbody H, Phillips D, Cooper C . Type 2 diabetes, muscle strength, and impaired physical function: the tip of the iceberg?. Diabetes Care. 2005; 28(10):2541-2. DOI: 10.2337/diacare.28.10.2541. View

19.

Suzuki K, Oikawa T, Nochioka K, Miura M, Kasahara S, Sato M . Elevated Serum Non-HDL (High-Density Lipoprotein) Cholesterol and Triglyceride Levels as Residual Risks for Myocardial Infarction Recurrence Under Statin Treatment. Arterioscler Thromb Vasc Biol. 2019; 39(5):934-944. DOI: 10.1161/ATVBAHA.119.312336. View

20.

Doehner W, Gerstein H, Ried J, Jung H, Asbrand C, Hess S . Obesity and weight loss are inversely related to mortality and cardiovascular outcome in prediabetes and type 2 diabetes: data from the ORIGIN trial. Eur Heart J. 2020; 41(28):2668-2677. PMC: 7377581. DOI: 10.1093/eurheartj/ehaa293. View